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Among 535 patients with invasive cervical carcinoma seen between January 1975 and June
1986, 26 were found to have developed the disease within six months (65 percent), 35 within 12
months (88 percent), 37 within 13 months (93 percent), and three developed thediseasewithin 17
months after a negative Papsmear. Eighty-eight percentofthese 40 patients were under age40 at
diagnosis. Rapidly progressive cancers are highly resistant to radiation therapy. Seven stage IB
patients treated only with radiation died within nine to 29 months after initial therapy. By
contrast, 15 patients treated by radical hysterectomy and four by radical hysterectomy and
post-surgical radiation werealive with noevidenceofdisease from six to 109 monthsaftersurgery
(median, 30 months). Six ofnine patients with stage II to IV disease treated with radiation have
died; the remaining three are alive. One patient is well 14 months after therapy, but two others
have developed metastases seven and 12 months after treatment. Surprisingly, 37 of 40 patients
had symptoms ofpain, bleeding, and discharge at the initial diagnosis, but their physicians had a
false sense ofsecurity because ofa recent negative Pap smear. Early biopsy diagnosis and radical
hysterectomy with bilateral pelvic lymphadenectomy is the most effective management for this
cancer.
INTRODUCTION
The report of a cytological technique for the diagnosis of pre-invasive or occult
cervical carcinoma by Papanicolaou and Traut in 1941 led to the assumption that
cervical cancer could be eliminated [1]. As early as 1952, however, clinical studies of
women screened by Pap smear indicated that invasive cervical cancer is not in all cases
preceded by in situ lesions [2]. This finding suggested that there may be two forms of
cervical cancer, biologically and clinically distinct, one ofwhich is rapidly progressive
and not detectable by routine Pap smear examination [3,4]. This paper will report on
the clinical management and survival of 40 young women diagnosed to have invasive
cervical cancer within a relatively short timeinterval from their last normal Pap smear.
It is assumed that these patients have what has been characterized as a rapidly
progressive form of cervical cancer, which shall be referred to as such in this paper.
Clinical, epidemiological, and tumor characteristics will be presented.
MATERIALS AND METHODS
During the period from January 1, 1975, through April 30, 1986, 40 patients who
developed invasive cervical cancer within 17 months ofa negative Pap smear were seen
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FIG. 1. Distribution by age of invasive cervical cancer patients at Yale-New Haven Hospital,
1/1/75-6/1/86.
at Yale-New Haven Hospital, New Haven, Connecticut. They were identified as
having the rapidly progressive form ofdisease. In the first six years ofthisstudy period,
11 cases were identified. Twenty-nine additional cases were observed during the latter
six years of the study period.
The series of 40 patients included 33 white women, five blacks, one Indian, and one
Vietnamese. This racial distribution is similar to that found in Connecticut. Patients
ranged in age from 20 to 54 years old, with the great majority (88 percent) less than 40
years old. Figure 1 illustrates the age distribution of the 40 patients in our series,
together with the age distribution for all patients with invasive cervical cancer seen at
Yale-New Haven Hospital during the same period.
Table I lists the symptoms experienced at time of diagnosis by patients with the
rapidly progressive disease. The most frequent symptoms were irregular bleeding (65
percent), pain (48 percent), and discharge (38 percent). Included under "irregular
bleeding" were any unusual types of bleeding, whether related to amount or timing.
Post-coital bleeding was noticed in 25 percent of women belonging to the sexually
active age group. Two of three women asymptomatic at the time of diagnosis were
found to have invasive cervical cancer by routine Pap smears.
The interval in months between diagnosis of invasive cervical cancer and last Pap
smear reported to be negative for cancer (class I or II) is illustrated in Fig. 2 for the 40
patients studied. The disease developed within six months of a negative Pap smear in
26 patients (65 percent); within 12 months in 35 patients (88 percent), and within 13
months in 37 patients (93 percent). For three patients, the disease developed within 17
months after a negative Pap smear. Whenever possible, records were reviewed and the
physical findings at the time of the last negative Pap smear were discussed with the
physician. Nopatient was reported to have a visible lesion present at the time ofthe last
negative smear prior to the diagnosis ofcervical cancer.
The FIGO clinical stage, histology, and grade of the patients' tumors are given in
Table 2. There were 28 patients with FIGO stage lB (70 percent): 23 squamous (82
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TABLE 1
Symptoms at Diagnosis for 40 Patients with Rapidly Progressive Cervical Cancer
Patients
Symptoms Number Percentage
Irregular bleeding 26 65
Pain (suprapubic, abdominal, lower back pain) 19 48
Vaginal discharge 15 38
Post-coital bleeding 10 25
Weight loss 3 8
Urinary incontinence 1 3
Asymptomatic 3 8
percent), four adenocarcinomas, and one adenosquamous carcinoma. All five patients
with stage IIB disease had squamous carcinomas. Among the five patients with stage
IIIB cancer, there were four squamous and one adenosquamous carcinoma. One
patient with a stage IVB tumor had a small-cell squamous carcinoma, and the other
had an adenosquamous carcinoma.
Tumors were histologically graded according to three groups, as illustrated in Table
2: grade 1 represented low-grade, i.e., well-differentiated cancers; grade 2, moderately
well-differentiated carcinoma; and grade 3, poorly differentiated malignancies and
anaplastic carcinomas. Initial treatments included six different modalities: type III
radical hysterectomy and bilateral pelvic lymphadenectomy, radiation only, type III
radical hysterectomy with bilateral pelvic lymphadenectomy followed by radiation,
radiation and simple hysterectomy, simple hysterectomy and radiation, and chemo-
therapy with radiation. For each stage, histology, and grade of tumor, the treatment
modality and the vital status at follow-up are also indicated in Table 2. Among stage
IB patients, a total of 15 patients underwent type III radical hysterectomies and
bilateral lymphadenectomies; seven were treated with radiation alone, four with type
III radical hysterectomies with bilateral pelvic lymphadenectomies and radiation, one
with radiation and simple hysterectomy, and another with simple hysterectomy and
radiation. Radiation only was the treatment given to all stage IIB, IIIB, and IVB
patients except in three cases. In two of these instances, simple hysterectomy and






2 FIG. 2. Interval in months
1 between diagnosis of inva-
0 sive cervical cancer and the
~sl 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 preceding negative Pap
Interval in Months smear.
329SCHWARTZ ET AL.
.4
- 4 4 e4 -







cis d C 0- -C
C:4









































































_ - * U
0

















P-4 W-4RAPIDLY PROGRESSING CERVICAL CANCER
were not recognized pre-operatively to have cervical cancer, and in one case the patient
received chemotherapy and radiation.
Although epidemiologic information was limited on these patients, it was noted that
23 patients (57.5 percent) were smokers or ex-smokers and 17 (42.5 percent) had never
smoked. Birth control pills had been taken by 20 women (50 percent) for various
lengths oftime, and another nine women (22.5 percent) reported having never been on
the pill. For 11 women the information was lacking (27.5 percent).
There were a total of 78 pregnancies prior to diagnosis (average 2.5) among 31
women with the rapidly progressive disease. Fifty-nine infants were born to 23
mothers, and 19 abortions were performed on 17 women.
RESULTS
The first ten patients' survival was previously reported [5] and is summarized below.
Eight patients recognized to have invasive cancer were managed in a standard fashion,
either with a type III radical hysterectomy and bilateral pelvic lymphadenectomy or
with intracavitary and external beam radiation therapy. The former treatment
modality was only routinely recommended at this institution for stage IB patients with
small primary cancers (less than 2 cm maximum diameter), histologically well- or
moderately well-differentiated, and with no evidence of vascular space infiltration.
Two patients with more advanced occult disease underwent primary routine hysterec-
tomies, as the diagnosis of cancer was not appreciated pre-operatively, followed by
post-operative whole-pelvis radiation therapy. A subsequent review revealed nine of
the initial ten patients to have died of cancer. The only survivor in this group was the
one 20-year-old patient who underwent a type III radical hysterectomy and bilateral
pelvic lymphadenectomy for a poorly differentiated squamous cell cancer 6 cm in
diameter and was found to have microscopic metastases to both pelvic side wall lymph
node chains. The latter patient received whole-pelvis external beam radiation therapy
post-operatively.
These findings led us to modify our approach to patients with cervical cancer
diagnosed within a short time period following a reportedly negative Pap smear. Each
patient with a stage IB cervical cancer, regardless of size of the primary cancer or its
histologic appearance, was recommended to undergo a type III radical hysterectomy
and bilateral pelvic lymphadenectomy. Patients found to have metastases to pelvic
lymph nodes or cancer microscopically encroaching on the surgical margins of
resection in the hysterectomy specimens were recommended to receive post-operative
radiation therapy to the whole pelvis. Patients with stage II to IV cancers were to
receive radiation therapy as the primary mode oftherapy.
The survival data for the entire series is summarized in Table 2, based on the stage
and the initial therapy. Fifteen patients with stage IB cancer treated with a type III
radical hysterectomy and bilateral pelvic lymphadenectomy are each alive and well
eight to 54 months following diagnosis (median, 31 months). Four patients with stage
IB cancers who underwent type III radical hysterectomies, bilateral pelvic lymphade-
nectomies, and post-operative whole-pelvis radiation therapy are alive and well 17 to
109 months following diagnosis (median, 251/2 months); however, each of seven
patients with stage IB cancer treated with radiation therapy alone has died from the
cancer nine to 29 months following diagnosis (median, 15 months), as have the two
remaining stage IB patients whounderwent either pelvic radiation followed by a simple
hysterectomy or a simple hysterectomy followed by radiation.
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TABLE 3
Histopathologic Findings in 16 Patients with Type III Radical Hysterectomy and Bilateral Pelvic




Invasion Space Infiltration Dysplasia Changes
Yes No Yes No Yes No Yes No
3(1) 13(5) 13(6) 3(0) 10(4) 6(2) 8(3) 8(3)
Twelve patients in this series had stage IIB to IVB disease. Six of nine patients
treated with standard radiation therapy alone have succumbed to cancer three to 35
months (median, 29 months) following diagnosis. Of the remaining three patients in
this group, one with stage IIB squamous lesions treated with radiation therapy is alive
15 months after treatment, but this patient has a documented liver metastasis. The
second patient, alsowith stage IIB squamouscarcinoma, treated with radiation, is alive
14 months after therapy. The third patient has stage IIIB squamous carcinoma and is
alive 12 months after the onset ofradiotherapy but with documented metastases to the
lung. Two patients who underwent a routine hysterectomy with radiation (one
preceding, the other following surgery) have died. The only patient who received
chemotherapy followed by radiation died nine months after diagnosis.
In an attempt to correlate histologic features with clinical findings, especially pain,
which was severe in many of these patients, a review of available surgical specimens
was performed by a gynecologic pathologist (MJM) on tumors from 24 patients in our
series. We were able to obtain slides from radical hysterectomies in 16 of 24 (66.7
percent) patients; in only eight cases was the slide review based solely on biopsy
material.
The histopathological findings are given in Table 3 for the 16 patients who
underwent radical hysterectomies. Among these latter patients with slide review, pain
was present in six and absent in ten of them. Three out of four patients with
adenocarcinoma of the cervix in our total study were found in the group of patients
without pain, as mentioned above. Perineural invasion was present in 17 percent of
specimens from patients with pain and in 20 percent of those pain-free. Vascular
and/or lymphatic space infiltration was noted in 100 percent and 70 percent ofpatients
with and without pain, respectively. There was no apparent correlation between the
presence of pain and the grade ofthe tumor.
Additionally, dysplasia was identified in ten out of the 16 patients and condyloma-
tous changes were visible in eight ofthese patients (Table 3).
DISCUSSION
The finding that at least 7 percent of patients referred to this institution had
negative Pap smears reported within a relatively short time prior to the diagnosis of
cervical cancerand thestrikingly rapid growth rateofthesemalignancies raises several
important issues. Does the entityofrapidly progressive cervical cancer really exist or is
it a reflection of false-negative Pap smear readings? What is the most effective
treatment for this cancer? How does one recognize patients at high risk forthis disease,
so that clinicians can more rapidly diagnose and care for such patients? Finally, are
there any significant histologic features that help to characterize these cancers?
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Does the entity ofrapidlyprogressive cervical cancer really exist? The presence ofa
rapidly progressive cervical cancer is surprisingly well documented in gynecologic and
epidemiologic literature. Based on data from the British Columbia Cervical Cancer
Screening Program [6], Albert [7], by using the mathematical modeling approach,
estimated that each year between 1.7 percent and 9.7 percent of all new cervical
cancers and about one-third ofall new "occult invasive" cases are diagnosed within one
year after a negative Pap smear, thus belonging to the rapidly progressive variety.
While earlier studies reported that older women were the target of the rapidly
progressive form ofcervical cancer [2,3,4,8,9], more recent publications have reported
that young women are more likely to be afflicted with this serious form of the disease
[5,10,11,12,13].
In 1976, Laskey, Meigs, and Flannery [10] gave evidence for two classes ofinvasive
cervical carcinoma based on the study of time trends in the Connecticut Tumor
Registry data for the 1935 to 1973 period. These authors supported theviews ofAshley
in the U.K. [4] and of Pedersen et al. in Norway [14] and postulated that one class of
cervical cancer was preceded by an in situ phase and developed slowly, while the other,
undetectable by screening, had a short pre-malignant stage and progressed rapidly.
They found this latter form in young women under 35.
In 1977, Rylander [11] reported that among 21 patients who were diagnosed, mostly
at a young age, as having invasive cervical cancer during the 1968-1974 period, four
(19 percent) developed their disease within one year and 11 (52 percent) within two
years following a negative Pap smear. None of these women had symptoms or visible
changes on the cervix at the time of cytological testing. Among the 21 patients, three
developed adenocarcinoma ofthe cervix.
Yule in 1978 [12] reported an increase in the rapidly progressive form of disease
among young women from the northwestern region of the United Kingdom. This
observation was made despite the fact that, in this region, the largest increase in Pap
smear testing had occurred in women under 35 years of age. He suggested that "the
pre-invasive phase of carcinoma of the cervix may be shorter in younger women,
leading more quickly to an aggressive invasive tumor which is less likely to be
prevented by routine screening unless the interval between tests is short." He also
suggested that screening programs may not be reaching the population at risk. Yule
postulated that the early onset ofsexual activity in the young and the increased use of
non-barrier contraceptives, particularly the contraceptive pill and intrauterine devices
which offer no protection against infectious agents, are likely to contribute to an
increased risk of cervical cancer in young women. In these patients, the disease
occurred without Pap smear findings ofa pre-invasive stage.
Berkowitz and his colleagues [13] reported on 27 women under 35 with invasive
cervical cancer, of whom 15 (55 percent) had negative or inadequate cervical smears
within the previous two years. All 15 women complained of irregular vaginal bleeding
or persistent vaginal discharge and were found to have clinically apparent cervical
lesions. Fourteen were diagnosed as having stage IB, and one had stage IIB. Overall,
among the 27 women in this study who were under 35 at diagnosis ofinvasive cervical
cancer, abnormal cervical cytology was the precipitating factor leading tothediagnosis
ofcervical cancer in only ten (37 percent) ofthese young women.
With the advent oflarge population-based cervical cancer screening programs, data
on rescreening of women previously found negative have become available. In a study
in Memphis-Shelby County, Dunn [15] reported that the proportion of newly
developing malignant cervical cancer cases was about one-third invasive and two-
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thirds in situ during the early years of the rescreening program. This proportion still
persisted after ten years of further screening [16]. Dunn concluded that two-thirds of
invasive cancers are preceded by an in situ phase, while the remaining one-third
progress rapidly to the invasive stage without an in situ phase.
Following 25 years of cervical cytology screening experience in Memphis-Shelby
County, Dunn [17] further reported that among 430 patients studied during the
1952-1978 period, 142 (33 percent) were cases of rapidly progressive cervical cancer.
The age distribution at diagnosis for these women indicated a higher proportion of
older women, as 84 (59 percent) were 39 and over while 58 (41 percent) were under
this age. The average interval from the last negative cytologic finding to diagnosis was
2.6 years.
In a study of invasive cervical cancer in Alameda County, California, from 1960 to
1974, Dunn [18] reported that 29 percent of women who developed invasive cervical
cancer during 1970-1974 had a history of a recently negative Pap smear. Over 70
percent ofthese women were diagnosed within two years ofa negative cytologic report.
In contrast to other studies, Dunn found this aggressive and rapidly progressive form of
cervical cancer to occur at all ages.
One must consider the possibility that many of the so-called "rapidly progressive
cervical cancers" represent nothing more than misread or false-negative Pap smears.
Berkeley et al. [5] reviewed the Pap smears ofthe first ten patients in the present series
and found that five patients had completely normal and adequate Pap smears (true
negative) within a ten-month period prior to the diagnoses ofinvasive cancer, while the
remaining five had changes requiring further investigation, i.e., false-negative Pap
smears. To date, cytology specimens have been reviewed from 22 patients in this series.
Twelve ofthe 22 cytology specimens were true negative Pap smears. Five patients had
false-negative Pap smears. Five patients had inadequate Pap smears due to (1) no
endocervical cells present, (2) scanty material, or (3) poor slide preparation.
Berkowitz et al. [13] reviewed so-called negative Pap smears from a group of ten
young women with rapidly progressive cervical cancer and found three to be true
negatives, five ofthe ten patients to have false-negative smears, and two others to have
inadequate Pap smears. This study illustrated that there is an increased risk of
false-negative Pap smears in cases ofcervical adenocarcinoma that may lead to failure
of diagnosis in the presence of mild symptoms [19]. Adenocarcinomas may arise in
deeper layers of the endocervical cavity and be less accessible than most squamous
cancers of the cervix. Cancers with a brief pre-clinical stage arising shortly after a
negative Pap smear may not be detectable by the Pap smear technique. Biological
variations in tumor and host factors may account for differences in cervical cell
exfoliation [3,4,20,21].
False-negative rates for Pap smear vary greatly from 12.5 percent [22] to 20 percent
to 45 percent [23]. Double sampling has been suggested in order to diminish the risk of
failure in specimen collection [24]; however, a 25 percent disparity in results has been
found between two slides obtained at the same time [25]. Thus, the practice of
obtaining repeat smears for confirmation ofcytologic findings is an unreliable method
to search for cervical pathology when conclusive confirmation is needed. Sampling
inefficiency had been thought to be the most important reason for false-negative Pap
smears [11]. The authors recommend annual Pap smears for sexually active women.
Patients must see their physicians promptly, however, for evaluation ofany pelvic pain,
vaginal discharge, or abnormal bleeding, regardless ofthe severity.
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What is the most effective treatment for rapidly progressive cervical cancer?
Radiation therapy has been employed at Yale-New Haven Hospital as standard
therapy for cervical cancer when unfavorable histologic features (poorly differentiated
cancers, lymphatic or vascular space invasion), bulky tumors, or advanced-stage
disease was present. Most patients in the present series qualified for standard radiation
therapy by these standards. A review of the first ten patients revealed nine of them to
have died rapidly from the disease. The only survivor had undergone a type III radical
hysterectomy and bilateral pelvic lymphadenectomy, was found to have microscopic
metastases to each pelvic side wall lymph node chain, and received post-operative
radiation therapy. Since that time, each patient with stage IB'cancer has been
recommended to undergo radical surgery regardless ofthe histologic appearance ofthe
cancer or the bulk oftumor present in the cervix. Post-operative radiation therapy was
offered to patients who had positive pelvic lymph nodes or cancer encroaching on the
surgical margins ofthe hysterectomy specimen. All but one patient have followed these
recommendations, and each of these patients is presently alive and well. The one
patient who elected to be treated with radiation therapy had previously been
successfully treated with a lumpectomy and radiation therapy for breast cancer and
did not want to undergo "mutilating" surgery. That patient subsequently developed a
metastasis of squamous cell cancer of uncertain origin to the left supraclavicular area
and has died.
Six of nine patients with stage II to IV cancer treated with standard radiation
therapy have had rapid progression of disease and have died. One of the remaining
three patients is alive and free of disease 14 months following diagnosis, while the
second and third patients are alive but have developed metastases, one in the lung and
the other in the liver, seven and 12 months, respectively, following diagnosis.
Berkowitz et al. [13] have reported on 27 patients under age 35, who had invasive
cervical cancer, 15 of whom had recently reported negative Pap smears. Twenty-four
of 25 patients with stage IB cancer were treated surgically, and each is alive and
disease-free. Three patients received prophylactic post-operative radiation therapy
because ofmetastases to pelvic lymph nodes and were free ofdisease at the time of the
report. One patient with lymph node metastases did not receive prophylactic radiation
therapy and developed a pelvic side wall recurrence six months later that responded to
radiation therapy. Two patients with stage IIB lesions were treated initially with
radiation therapy, and each developed pulmonary metastases, one while receiving
radiation therapy and the other eight months following completion of radiation
therapy.
The experience in the present series and the report of Berkowitz et al. support the
role of surgery as the initial step in the management of rapidly progressive cervical
cancer and subsequent post-operative radiation therapy if unfavorable histologic
findings are present. Patients with advanced-stage disease do not appear to benefit
from radiation therapy alone, and new strategies for management will have to be
devised. These techniques might include systemic or intra-arterial chemotherapy with
or without radiation therapy or surgery or primary exenterative surgery. Multi-
institutional studies will be necessary to confirm our observations before new treatment
strategies are to be attempted.
How are we to recognize patients at high risk for rapidly progressive cervical
cancer, and how can we rapidly diagnose and treat such patients? Patients at high risk
for rapidly progressive cervical cancer have yet to be characterized. Examining the
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patients in the present series suggests thatthese patients areoften underage40, smoke,
and have used oral contraceptives. Parity does not appear to be associated with this
process. Additionally, most patients are symptomatic at presentation despite the fact
that 75 percent are identified when the cancer is still confined to the cervix.
Symptoms experienced by 37 of the 40 patients in this study included irregular
bleeding or abnormal menses (65 percent) and vaginal discharge (38 percent). We
consider that the high frequency of pain in our patients (48 percent), whether
abdominal, suprapubic, or lower back pain, is somewhat characteristic of the rapidly
progressive form ofcervical cancer and should alert the physician, since this complaint
is not as frequently found among other patients with cervical cancer.
Epidemiologic studies have suggested that venereal diseases such as herpes simplex
virus (HSV2), cytomegalovirus (CMV), and human papilloma virus (HPV) may play
a role in the development of invasive cervical cancer [26,27,28]. Several studies have
shown that HPV types 16, 18, and 31 are more likely to be associated with invasive
cervical cancer, while types 6 and 11 are found and more readily identified in cases of
dysplasia and carcinoma in situ [29]. Barnes and associates have recently presented
data suggesting that HPV type 18 may be associated with rapidly progressive cervical
cancer [30]. Condylomatous changes were frequently found to be present histologi-
cally in patients with rapidly progressive cervical cancer (Table 3), but subtyping of
HPV was not performed.
Are any significant cytologic or histologic features present that could help to
identify rapidly progressive cervical cancer? A preliminary review of histologic
material from patients in this study suggests that most cancers are histologically
moderate or poorly differentiated squamous carcinomas. Perineural infiltration of
cancer within the cervix itselfhas been noted in some radical hysterectomy specimens
but not specifically associated with those patients presenting with pelvic pain (Table
3). Capillary space involvement was frequently observed, but no histologically
distinguishing features have been noted to date. A more extensivehistologic review will
be performed as more histologic and cytologic materials become available.
A consistent finding in this study was the security that gynecologists placed on a
reportedly negative Pap smear despite the frequent presence of visual lesions on the
cervix. Discussions with gynecologists caring for these patients revealed a lack of
knowledge that a patient who underwent routine Pap smear screening could develop
invasive cancer less than one year from the last reported negative Pap smear.
The message has been clear toboth physicians and patients that a positivePap smear
requires prompt evaluation; however, the corollary has yet to be demonstrated to be
true. Taylor [1], in his discussion of Papanicolaou and Traut's 1941 paper on the
diagnostic value ofvaginal smears in cancer ofthe uterus, stated that three steps must
be taken for routine cytologic screening to be effective. The first was to demonstrate
that a positive Pap smear meant cancer was present. The second was described as more
difficult and more important than the first one: to demonstrate that a negative smear
meant cancer was not present. The third step was to organize medical practice to
employ this test routinely. A negative Pap smear does not guarantee that a patient is
freeofcervical or uterinecancer. Apatient with avisiblecervical lesion orsymptoms of
pain, discharge, or bleeding requires evaluation beyond a Pap smear. A negative Pap
smear under these circumstances does not ensure the absence of malignancy, and
evaluation includingcolposcopyand biopsiesofthecervix and theendocervix should be
promptly performed.
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We are in the process of reviewing the cytology and pathology of all available Pap
smears and cervical tissues from patients in our study. It is imperative, however, to
keep in mind that a negative Pap smear report has an effect that will subsequently
determine the course of events. A negative Pap smear, whether shown later on to be
truly or falsely negative, will at the time ofthe negative report influence attitudes and
decisions of both the physician and the patient and therefore have a definite effect on
the woman's survival. Those patients who were successfully treated to date are limited
to those who have had stage IB cancer and underwent a radical hysterectomy and
bilateral pelvic lymphadenectomy. Prompt diagnosis and surgery are essential for the
management ofpatients with rapidly progressive cervical cancer.
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